LUX-Lung 5: Afatinib Plus Weekly Paclitaxel Versus Investigator's Choice of Single Agent Chemotherapy Following Afatinib Monotherapy in Non-small Cell Lung Cancer Patients Failing Erlotinib or Gefitinib
This study is ongoing, but not recruiting participants.
Study NCT01085136
Information provided by Boehringer Ingelheim Pharmaceuticals
First Received on March 10, 2010.
Last Updated on May 15, 2013
History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
